<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02132767</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 08-1078-00007</org_study_id>
    <secondary_id>5U01HL088942-08</secondary_id>
    <nct_id>NCT02132767</nct_id>
  </id_info>
  <brief_title>Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation</brief_title>
  <official_title>Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the therapeutic strategies of rate control versus
      rhythm control in cardiac surgery patients who develop in-hospital postoperative atrial
      fibrillation or atrial flutter (AF). In patients who develop AF during hospitalization after
      cardiac surgery, the hypothesis is that a strategy of rhythm control will reduce days in
      hospital within 60 days of the occurrence of AF compared to a strategy of rate control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the research is to compare two strategies for treating atrial fibrillation or
      atrial flutter, both of which are referred to as AF, after cardiac surgery. AF is the most
      common complication after cardiac surgery. AF is when the upper chambers of the heart (atria)
      experience disorganized electrical activity which causes the heart beat to be irregular. The
      two treatment strategies to be used in this study are called rhythm control and rate control.
      The rhythm control strategy will attempt to bring the heart beat back to a regular rhythm
      using treatments known and approved to control heart rhythm. The rate control strategy will
      attempt to bring the heart rate to less than 100 beats per minute at rest using medications
      known and recommended to control heart rate. Both strategies are commonly used to treat AF.
      All of the medications that will be used in this study are the standard of care for use in
      patients experiencing AF. This research seeks to determine whether rhythm control is better
      than rate control in patients with AF after cardiac surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Days in Hospital</measure>
    <time_frame>Within 60 days of randomization</time_frame>
    <description>The total number of days in hospital for any hospitalization that occurs within 60 days of randomization to AF treatment strategy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Conversion to Sustained, Stable Non-AF Rhythm</measure>
    <time_frame>Up to index hospital discharge or 7 days post surgery, whichever came first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rhythm Comparison</measure>
    <time_frame>Hospital discharge</time_frame>
    <description>Compare heart rhythm (number of patients in sustained, stable non-AF rhythm) between treatment arms at hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rhythm Comparison</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Compare heart rhythm (patients in sustained, stable non-AF rhythm) between treatment arms at 30 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rhythm Comparison</measure>
    <time_frame>60 days after randomization</time_frame>
    <description>Compare heart rhythm (number of patients in sustained, stable non-AF rhythm) between treatment arms at 60 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay (Index Hospitalization)</measure>
    <time_frame>Within 60 days post surgery</time_frame>
    <description>Overall length of stay for the index hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay (Rehospitalization, Including ED Visits)</measure>
    <time_frame>Within 60 days of randomization</time_frame>
    <description>Compare frequency of readmissions between groups for any cause and AF-related hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outpatient Interventions</measure>
    <time_frame>Within 60 days of randomization</time_frame>
    <description>Compare frequency of outpatient visits between groups for any cause and AF-related causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF- or Treatment-related Events</measure>
    <time_frame>Within 60 days of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost (Hospital)</measure>
    <time_frame>Within 60 days of randomization</time_frame>
    <description>Compare cost of index hospitalization and cost of rehospitalizations (including ED visits) between groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">523</enrollment>
  <condition>Postoperative Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Rhythm control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rhythm Control in post-operative AF
Amiodarone and/or DC-cardioversion
Amiodarone Initial Dose
Oral: 400 mg po TID for 3 days is recommended
For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose
Oral: at least 200 mg/day to be continued until 60 days after randomization
If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started
DC-Cardioversion - frequency and duration determined by medical professional as medically needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rate control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rate Control in post-operative AF
Beta-blocker and/or Calcium channel blockers and/or Digoxin
Dose, frequency and duration determined by medical professional as medically needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Amiodarone Initial Dose
Oral: 400 mg po TID for 3 days is recommended
For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose
Oral: at least 200 mg/day to be continued until 60 days after randomization
If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started</description>
    <arm_group_label>Rhythm control</arm_group_label>
    <other_name>Cordarone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DC-cardioversion</intervention_name>
    <description>DC-Cardioversion - frequency and duration determined by medical professional as medically needed</description>
    <arm_group_label>Rhythm control</arm_group_label>
    <other_name>Direct Current Cardioversion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rate Control</intervention_name>
    <description>Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed</description>
    <arm_group_label>Rate control</arm_group_label>
    <other_name>Beta-blocker</other_name>
    <other_name>Calcium channel blockers</other_name>
    <other_name>Digoxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Enrollment Inclusion Criteria:

          -  Age &gt; 18 years

          -  Undergoing heart surgery for coronary artery bypass (on-pump or off-pump CABG) and/or
             valve repair or replacement (excluding mechanical valves), including re-operations

          -  Hemodynamically stable

        Randomization Inclusion Criteria

          -  AF that persists for &gt; 60 minutes or recurrent (more than one) episodes of AF up to 7
             days after surgery during the index hospitalization.

        Exclusion Criteria:

          -  LVAD insertion or heart transplantation

          -  Maze procedure

          -  TAVR

          -  History of or planned mechanical valve replacement

          -  Correction of complex congenital cardiac defect (excluding bicuspid aortic valve,
             atrial septal defect or PFO)

          -  History of AF or AFL

          -  History of AF or AFL ablation

          -  Contraindications to warfarin or amiodarone

          -  Need for long-term anticoagulation

          -  Concurrent participation in an interventional (drug or device) trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Wiesel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiothoracic Surgical Trials Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick T O'Gara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiothoracic Surgical Trials Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIH Heart Center at Suburban Hospital</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health Services</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Heart Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health Systems</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Cœur de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie de Quebec (Hopital Laval)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ctsurgerynet.org/</url>
    <description>Cardiothoracic Surgical Trials Network Website</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2014</study_first_submitted>
  <study_first_submitted_qc>May 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2014</study_first_posted>
  <results_first_submitted>September 30, 2016</results_first_submitted>
  <results_first_submitted_qc>November 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2017</results_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Annetine Gelijns</investigator_full_name>
    <investigator_title>Professor and Chair, Health Evidence and Policy</investigator_title>
  </responsible_party>
  <keyword>Heart surgery</keyword>
  <keyword>Cardiac surgery</keyword>
  <keyword>Coronary artery bypass</keyword>
  <keyword>Mitral valve surgery</keyword>
  <keyword>Aortic valve surgery</keyword>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Atrial flutter</keyword>
  <keyword>Cardiac arrhythmia</keyword>
  <keyword>Valve surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rate Control</title>
          <description>Patients randomized to this arm will be treated with an initial strategy of rate control. The target heart rate is &lt; 100 beats per minute at rest. The treating clinician will choose agents from the list of rate control medications below and employ these medications (singly or in combination) to achieve rate control. A patient who presents with AF and slow ventricular response rate (&lt;60 beats per minute) may still be randomized to the rate control strategy; in such instances, rate control agents may be withheld or administered in low doses. Dose ranges, as defined in guidelines, for each of the rate control agents need to be adhered to. Simultaneous use of more than one of the categories of rate control agents should be done with caution due to risk of bradycardia.
Rate Control Agents:
Beta blockers (e.g. metoprolol, atenolol, carvedilol, esmolol) Calcium channel blockers (nondihydropyridine) (e.g. diltiazem, verapamil) Digoxin</description>
        </group>
        <group group_id="P2">
          <title>Rhythm Control</title>
          <description>Patients assigned to an initial strategy of rhythm control will be treated with amiodarone alone or amiodarone plus direct current (DC) cardioversion if amiodarone alone does not eliminate AF within 48 hours. For patients who are hemodynamically stable but remain in AF, at least 24 hours of amiodarone should be administered before cardioversion is attempted. Cardioversion should be attempted, if possible, prior to the 48 hour duration to avoid the need for a TEE guided approach.
If AF has been present for ≥ 48 hours and the patient has not been therapeutically anticoagulated, cardioversion should be TEE guided. When deemed to be clinically appropriate, patients in the rhythm control arm may also be treated with a rate control medication (e.g. beta blocker). In particular, a rate control medication may be indicated at the onset of AF.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="262"/>
                <participants group_id="P2" count="261"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
                <participants group_id="P2" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized patients</population>
      <group_list>
        <group group_id="B1">
          <title>Rate Control</title>
          <description>Patients randomized to this arm will be treated with an initial strategy of rate control. The target heart rate is &lt; 100 beats per minute at rest. The treating clinician will choose agents from the list of rate control medications below and employ these medications (singly or in combination) to achieve rate control. A patient who presents with AF and slow ventricular response rate (&lt;60 beats per minute) may still be randomized to the rate control strategy; in such instances, rate control agents may be withheld or administered in low doses. Dose ranges, as defined in guidelines, for each of the rate control agents need to be adhered to. Simultaneous use of more than one of the categories of rate control agents should be done with caution due to risk of bradycardia.
Rate Control Agents:
Beta blockers (e.g. metoprolol, atenolol, carvedilol, esmolol) Calcium channel blockers (nondihydropyridine) (e.g. diltiazem, verapamil) Digoxin</description>
        </group>
        <group group_id="B2">
          <title>Rhythm Control</title>
          <description>Patients assigned to an initial strategy of rhythm control will be treated with amiodarone alone or amiodarone plus direct current (DC) cardioversion if amiodarone alone does not eliminate AF within 48 hours. For patients who are hemodynamically stable but remain in AF, at least 24 hours of amiodarone should be administered before cardioversion is attempted. Cardioversion should be attempted, if possible, prior to the 48 hour duration to avoid the need for a TEE guided approach.
If AF has been present for ≥ 48 hours and the patient has not been therapeutically anticoagulated, cardioversion should be TEE guided. When deemed to be clinically appropriate, patients in the rhythm control arm may also be treated with a rate control medication (e.g. beta blocker). In particular, a rate control medication may be indicated at the onset of AF.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="262"/>
            <count group_id="B2" value="261"/>
            <count group_id="B3" value="523"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.2" spread="9.8"/>
                    <measurement group_id="B2" value="68.4" spread="8.4"/>
                    <measurement group_id="B3" value="68.8" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="249"/>
                    <measurement group_id="B3" value="501"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="250"/>
                    <measurement group_id="B3" value="492"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Days in Hospital</title>
        <description>The total number of days in hospital for any hospitalization that occurs within 60 days of randomization to AF treatment strategy.</description>
        <time_frame>Within 60 days of randomization</time_frame>
        <population>All randomized patients (intent to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Rate Control</title>
            <description>Patients randomized to this arm will be treated with an initial strategy of rate control. The target heart rate is &lt; 100 beats per minute at rest. The treating clinician will choose agents from the list of rate control medications below and employ these medications (singly or in combination) to achieve rate control. A patient who presents with AF and slow ventricular response rate (&lt;60 beats per minute) may still be randomized to the rate control strategy; in such instances, rate control agents may be withheld or administered in low doses. Dose ranges, as defined in guidelines, for each of the rate control agents need to be adhered to. Simultaneous use of more than one of the categories of rate control agents should be done with caution due to risk of bradycardia.
Rate Control Agents:
Beta blockers (e.g. metoprolol, atenolol, carvedilol, esmolol) Calcium channel blockers (nondihydropyridine) (e.g. diltiazem, verapamil) Digoxin</description>
          </group>
          <group group_id="O2">
            <title>Rhythm Control</title>
            <description>Patients assigned to an initial strategy of rhythm control will be treated with amiodarone alone or amiodarone plus direct current (DC) cardioversion if amiodarone alone does not eliminate AF within 48 hours. For patients who are hemodynamically stable but remain in AF, at least 24 hours of amiodarone should be administered before cardioversion is attempted. Cardioversion should be attempted, if possible, prior to the 48 hour duration to avoid the need for a TEE guided approach.
If AF has been present for ≥ 48 hours and the patient has not been therapeutically anticoagulated, cardioversion should be TEE guided. When deemed to be clinically appropriate, patients in the rhythm control arm may also be treated with a rate control medication (e.g. beta blocker). In particular, a rate control medication may be indicated at the onset of AF.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Days in Hospital</title>
          <description>The total number of days in hospital for any hospitalization that occurs within 60 days of randomization to AF treatment strategy.</description>
          <population>All randomized patients (intent to treat)</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="3.0" upper_limit="7.4"/>
                    <measurement group_id="O2" value="5.0" lower_limit="3.2" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Conversion to Sustained, Stable Non-AF Rhythm</title>
        <time_frame>Up to index hospital discharge or 7 days post surgery, whichever came first</time_frame>
        <population>All randomized patients (intent to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Rate Control</title>
            <description>Patients randomized to this arm will be treated with an initial strategy of rate control. The target heart rate is &lt; 100 beats per minute at rest. The treating clinician will choose agents from the list of rate control medications below and employ these medications (singly or in combination) to achieve rate control. A patient who presents with AF and slow ventricular response rate (&lt;60 beats per minute) may still be randomized to the rate control strategy; in such instances, rate control agents may be withheld or administered in low doses. Dose ranges, as defined in guidelines, for each of the rate control agents need to be adhered to. Simultaneous use of more than one of the categories of rate control agents should be done with caution due to risk of bradycardia.
Rate Control Agents:
Beta blockers (e.g. metoprolol, atenolol, carvedilol, esmolol) Calcium channel blockers (nondihydropyridine) (e.g. diltiazem, verapamil) Digoxin</description>
          </group>
          <group group_id="O2">
            <title>Rhythm Control</title>
            <description>Patients assigned to an initial strategy of rhythm control will be treated with amiodarone alone or amiodarone plus direct current (DC) cardioversion if amiodarone alone does not eliminate AF within 48 hours. For patients who are hemodynamically stable but remain in AF, at least 24 hours of amiodarone should be administered before cardioversion is attempted. Cardioversion should be attempted, if possible, prior to the 48 hour duration to avoid the need for a TEE guided approach.
If AF has been present for ≥ 48 hours and the patient has not been therapeutically anticoagulated, cardioversion should be TEE guided. When deemed to be clinically appropriate, patients in the rhythm control arm may also be treated with a rate control medication (e.g. beta blocker). In particular, a rate control medication may be indicated at the onset of AF.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Conversion to Sustained, Stable Non-AF Rhythm</title>
          <population>All randomized patients (intent to treat)</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" lower_limit="0.46" upper_limit="4.81"/>
                    <measurement group_id="O2" value="0.95" lower_limit="0.27" upper_limit="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rhythm Comparison</title>
        <description>Compare heart rhythm (number of patients in sustained, stable non-AF rhythm) between treatment arms at hospital discharge</description>
        <time_frame>Hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rate Control</title>
            <description>Patients randomized to this arm will be treated with an initial strategy of rate control. The target heart rate is &lt; 100 beats per minute at rest. The treating clinician will choose agents from the list of rate control medications below and employ these medications (singly or in combination) to achieve rate control. A patient who presents with AF and slow ventricular response rate (&lt;60 beats per minute) may still be randomized to the rate control strategy; in such instances, rate control agents may be withheld or administered in low doses. Dose ranges, as defined in guidelines, for each of the rate control agents need to be adhered to. Simultaneous use of more than one of the categories of rate control agents should be done with caution due to risk of bradycardia.
Rate Control Agents:
Beta blockers (e.g. metoprolol, atenolol, carvedilol, esmolol) Calcium channel blockers (nondihydropyridine) (e.g. diltiazem, verapamil) Digoxin</description>
          </group>
          <group group_id="O2">
            <title>Rhythm Control</title>
            <description>Patients assigned to an initial strategy of rhythm control will be treated with amiodarone alone or amiodarone plus direct current (DC) cardioversion if amiodarone alone does not eliminate AF within 48 hours. For patients who are hemodynamically stable but remain in AF, at least 24 hours of amiodarone should be administered before cardioversion is attempted. Cardioversion should be attempted, if possible, prior to the 48 hour duration to avoid the need for a TEE guided approach.
If AF has been present for ≥ 48 hours and the patient has not been therapeutically anticoagulated, cardioversion should be TEE guided. When deemed to be clinically appropriate, patients in the rhythm control arm may also be treated with a rate control medication (e.g. beta blocker). In particular, a rate control medication may be indicated at the onset of AF.</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rhythm Comparison</title>
          <description>Compare heart rhythm (number of patients in sustained, stable non-AF rhythm) between treatment arms at hospital discharge</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rhythm Comparison</title>
        <description>Compare heart rhythm (patients in sustained, stable non-AF rhythm) between treatment arms at 30 days after randomization</description>
        <time_frame>30 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rate Control</title>
            <description>Patients randomized to this arm will be treated with an initial strategy of rate control. The target heart rate is &lt; 100 beats per minute at rest. The treating clinician will choose agents from the list of rate control medications below and employ these medications (singly or in combination) to achieve rate control. A patient who presents with AF and slow ventricular response rate (&lt;60 beats per minute) may still be randomized to the rate control strategy; in such instances, rate control agents may be withheld or administered in low doses. Dose ranges, as defined in guidelines, for each of the rate control agents need to be adhered to. Simultaneous use of more than one of the categories of rate control agents should be done with caution due to risk of bradycardia.
Rate Control Agents:
Beta blockers (e.g. metoprolol, atenolol, carvedilol, esmolol) Calcium channel blockers (nondihydropyridine) (e.g. diltiazem, verapamil) Digoxin</description>
          </group>
          <group group_id="O2">
            <title>Rhythm Control</title>
            <description>Patients assigned to an initial strategy of rhythm control will be treated with amiodarone alone or amiodarone plus direct current (DC) cardioversion if amiodarone alone does not eliminate AF within 48 hours. For patients who are hemodynamically stable but remain in AF, at least 24 hours of amiodarone should be administered before cardioversion is attempted. Cardioversion should be attempted, if possible, prior to the 48 hour duration to avoid the need for a TEE guided approach.
If AF has been present for ≥ 48 hours and the patient has not been therapeutically anticoagulated, cardioversion should be TEE guided. When deemed to be clinically appropriate, patients in the rhythm control arm may also be treated with a rate control medication (e.g. beta blocker). In particular, a rate control medication may be indicated at the onset of AF.</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rhythm Comparison</title>
          <description>Compare heart rhythm (patients in sustained, stable non-AF rhythm) between treatment arms at 30 days after randomization</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.71</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rhythm Comparison</title>
        <description>Compare heart rhythm (number of patients in sustained, stable non-AF rhythm) between treatment arms at 60 days after randomization</description>
        <time_frame>60 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rate Control</title>
            <description>Patients randomized to this arm will be treated with an initial strategy of rate control. The target heart rate is &lt; 100 beats per minute at rest. The treating clinician will choose agents from the list of rate control medications below and employ these medications (singly or in combination) to achieve rate control. A patient who presents with AF and slow ventricular response rate (&lt;60 beats per minute) may still be randomized to the rate control strategy; in such instances, rate control agents may be withheld or administered in low doses. Dose ranges, as defined in guidelines, for each of the rate control agents need to be adhered to. Simultaneous use of more than one of the categories of rate control agents should be done with caution due to risk of bradycardia.
Rate Control Agents:
Beta blockers (e.g. metoprolol, atenolol, carvedilol, esmolol) Calcium channel blockers (nondihydropyridine) (e.g. diltiazem, verapamil) Digoxin</description>
          </group>
          <group group_id="O2">
            <title>Rhythm Control</title>
            <description>Patients assigned to an initial strategy of rhythm control will be treated with amiodarone alone or amiodarone plus direct current (DC) cardioversion if amiodarone alone does not eliminate AF within 48 hours. For patients who are hemodynamically stable but remain in AF, at least 24 hours of amiodarone should be administered before cardioversion is attempted. Cardioversion should be attempted, if possible, prior to the 48 hour duration to avoid the need for a TEE guided approach.
If AF has been present for ≥ 48 hours and the patient has not been therapeutically anticoagulated, cardioversion should be TEE guided. When deemed to be clinically appropriate, patients in the rhythm control arm may also be treated with a rate control medication (e.g. beta blocker). In particular, a rate control medication may be indicated at the onset of AF.</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rhythm Comparison</title>
          <description>Compare heart rhythm (number of patients in sustained, stable non-AF rhythm) between treatment arms at 60 days after randomization</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay (Index Hospitalization)</title>
        <description>Overall length of stay for the index hospitalization</description>
        <time_frame>Within 60 days post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rate Control</title>
            <description>Patients randomized to this arm will be treated with an initial strategy of rate control. The target heart rate is &lt; 100 beats per minute at rest. The treating clinician will choose agents from the list of rate control medications below and employ these medications (singly or in combination) to achieve rate control. A patient who presents with AF and slow ventricular response rate (&lt;60 beats per minute) may still be randomized to the rate control strategy; in such instances, rate control agents may be withheld or administered in low doses. Dose ranges, as defined in guidelines, for each of the rate control agents need to be adhered to. Simultaneous use of more than one of the categories of rate control agents should be done with caution due to risk of bradycardia.
Rate Control Agents:
Beta blockers (e.g. metoprolol, atenolol, carvedilol, esmolol) Calcium channel blockers (nondihydropyridine) (e.g. diltiazem, verapamil) Digoxin</description>
          </group>
          <group group_id="O2">
            <title>Rhythm Control</title>
            <description>Patients assigned to an initial strategy of rhythm control will be treated with amiodarone alone or amiodarone plus direct current (DC) cardioversion if amiodarone alone does not eliminate AF within 48 hours. For patients who are hemodynamically stable but remain in AF, at least 24 hours of amiodarone should be administered before cardioversion is attempted. Cardioversion should be attempted, if possible, prior to the 48 hour duration to avoid the need for a TEE guided approach.
If AF has been present for ≥ 48 hours and the patient has not been therapeutically anticoagulated, cardioversion should be TEE guided. When deemed to be clinically appropriate, patients in the rhythm control arm may also be treated with a rate control medication (e.g. beta blocker). In particular, a rate control medication may be indicated at the onset of AF.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay (Index Hospitalization)</title>
          <description>Overall length of stay for the index hospitalization</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="2.9" upper_limit="6.6"/>
                    <measurement group_id="O2" value="4.3" lower_limit="3.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay (Rehospitalization, Including ED Visits)</title>
        <description>Compare frequency of readmissions between groups for any cause and AF-related hospitalizations</description>
        <time_frame>Within 60 days of randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rate Control</title>
            <description>Patients randomized to this arm will be treated with an initial strategy of rate control. The target heart rate is &lt; 100 beats per minute at rest. The treating clinician will choose agents from the list of rate control medications below and employ these medications (singly or in combination) to achieve rate control. A patient who presents with AF and slow ventricular response rate (&lt;60 beats per minute) may still be randomized to the rate control strategy; in such instances, rate control agents may be withheld or administered in low doses. Dose ranges, as defined in guidelines, for each of the rate control agents need to be adhered to. Simultaneous use of more than one of the categories of rate control agents should be done with caution due to risk of bradycardia.
Rate Control Agents:
Beta blockers (e.g. metoprolol, atenolol, carvedilol, esmolol) Calcium channel blockers (nondihydropyridine) (e.g. diltiazem, verapamil) Digoxin</description>
          </group>
          <group group_id="O2">
            <title>Rhythm Control</title>
            <description>Patients assigned to an initial strategy of rhythm control will be treated with amiodarone alone or amiodarone plus direct current (DC) cardioversion if amiodarone alone does not eliminate AF within 48 hours. For patients who are hemodynamically stable but remain in AF, at least 24 hours of amiodarone should be administered before cardioversion is attempted. Cardioversion should be attempted, if possible, prior to the 48 hour duration to avoid the need for a TEE guided approach.
If AF has been present for ≥ 48 hours and the patient has not been therapeutically anticoagulated, cardioversion should be TEE guided. When deemed to be clinically appropriate, patients in the rhythm control arm may also be treated with a rate control medication (e.g. beta blocker). In particular, a rate control medication may be indicated at the onset of AF.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay (Rehospitalization, Including ED Visits)</title>
          <description>Compare frequency of readmissions between groups for any cause and AF-related hospitalizations</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.6" upper_limit="5.0"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.0" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outpatient Interventions</title>
        <description>Compare frequency of outpatient visits between groups for any cause and AF-related causes</description>
        <time_frame>Within 60 days of randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rate Control</title>
            <description>Patients randomized to this arm will be treated with an initial strategy of rate control. The target heart rate is &lt; 100 beats per minute at rest. The treating clinician will choose agents from the list of rate control medications below and employ these medications (singly or in combination) to achieve rate control. A patient who presents with AF and slow ventricular response rate (&lt;60 beats per minute) may still be randomized to the rate control strategy; in such instances, rate control agents may be withheld or administered in low doses. Dose ranges, as defined in guidelines, for each of the rate control agents need to be adhered to. Simultaneous use of more than one of the categories of rate control agents should be done with caution due to risk of bradycardia.
Rate Control Agents:
Beta blockers (e.g. metoprolol, atenolol, carvedilol, esmolol) Calcium channel blockers (nondihydropyridine) (e.g. diltiazem, verapamil) Digoxin</description>
          </group>
          <group group_id="O2">
            <title>Rhythm Control</title>
            <description>Patients assigned to an initial strategy of rhythm control will be treated with amiodarone alone or amiodarone plus direct current (DC) cardioversion if amiodarone alone does not eliminate AF within 48 hours. For patients who are hemodynamically stable but remain in AF, at least 24 hours of amiodarone should be administered before cardioversion is attempted. Cardioversion should be attempted, if possible, prior to the 48 hour duration to avoid the need for a TEE guided approach.
If AF has been present for ≥ 48 hours and the patient has not been therapeutically anticoagulated, cardioversion should be TEE guided. When deemed to be clinically appropriate, patients in the rhythm control arm may also be treated with a rate control medication (e.g. beta blocker). In particular, a rate control medication may be indicated at the onset of AF.</description>
          </group>
        </group_list>
        <measure>
          <title>Outpatient Interventions</title>
          <description>Compare frequency of outpatient visits between groups for any cause and AF-related causes</description>
          <units>hospital stays &lt; 24 hours</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Regression, Poisson</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AF- or Treatment-related Events</title>
        <time_frame>Within 60 days of randomization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cost (Hospital)</title>
        <description>Compare cost of index hospitalization and cost of rehospitalizations (including ED visits) between groups</description>
        <time_frame>Within 60 days of randomization</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rate Control</title>
          <description>Patients randomized to this arm will be treated with an initial strategy of rate control. The target heart rate is &lt; 100 beats per minute at rest. The treating clinician will choose agents from the list of rate control medications below and employ these medications (singly or in combination) to achieve rate control. A patient who presents with AF and slow ventricular response rate (&lt;60 beats per minute) may still be randomized to the rate control strategy; in such instances, rate control agents may be withheld or administered in low doses. Dose ranges, as defined in guidelines, for each of the rate control agents need to be adhered to. Simultaneous use of more than one of the categories of rate control agents should be done with caution due to risk of bradycardia.
Rate Control Agents:
Beta blockers (e.g. metoprolol, atenolol, carvedilol, esmolol) Calcium channel blockers (nondihydropyridine) (e.g. diltiazem, verapamil) Digoxin</description>
        </group>
        <group group_id="E2">
          <title>Rhythm Control</title>
          <description>Patients assigned to an initial strategy of rhythm control will be treated with amiodarone alone or amiodarone plus direct current (DC) cardioversion if amiodarone alone does not eliminate AF within 48 hours. For patients who are hemodynamically stable but remain in AF, at least 24 hours of amiodarone should be administered before cardioversion is attempted. Cardioversion should be attempted, if possible, prior to the 48 hour duration to avoid the need for a TEE guided approach.
If AF has been present for ≥ 48 hours and the patient has not been therapeutically anticoagulated, cardioversion should be TEE guided. When deemed to be clinically appropriate, patients in the rhythm control arm may also be treated with a rate control medication (e.g. beta blocker). In particular, a rate control medication may be indicated at the onset of AF.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmias</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="262"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="262"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pericardial Fluid Collection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="262"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypotension/Syncope</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="262"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="262"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Post-Pericardiotomy Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="262"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Ischemic Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Small Bowel Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="262"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Nosocomial Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Major Infection</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="262"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Coumadin Toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Amiodarone Toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Fall Not Related to Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Heparin-Induced Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Right Groin Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Sternal Wound Dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Thromboembolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="262"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Peripheral Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Events</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="262"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="262"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="262"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Non-Cerebral Thromboembolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Cerebral Thromboembolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="262"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Thrombus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Peripheral Vascular Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="262"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="262"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmias</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="262"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="262"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Major infection</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="262"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal events</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="262"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="262"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Superficial venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis left limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Annetine C. Gelijns, PhD</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-659-9568</phone>
      <email>annetine.gelijns@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

